Participation of patients with early hormone-dependent, HER2-negative breast cancer in adjuvant treatment with aromatase inhibitors with or without abemaciclib

Improving support for patients during treatment and increasing treatment effectiveness.

It is known that medicines used to treat hormone receptor-positive, HER2-negative breast cancer may cause side effects, which can often lead to missed doses or even discontinuation of treatment. In this study, we aim to collect data that will help improve support for patients during treatment and thereby increase the effectiveness of the medicines.

Purpose of the study

To better understand how consistently patients follow the prescribed treatment and which factors influence possible discontinuation of medication.

Study procedure

All participants will receive standard treatment, regardless of whether they take part in the study. Participation includes four visits, which will take place alongside regular oncology appointments. During these visits, you will report any possible side effects of the medicines and how regularly you are taking them.

In addition, you will complete several questionnaires covering quality of life, cognitive functioning and basic demographic characteristics. You may complete the questionnaires after your appointment or at home and return them at your next visit. After three and six months, you will also bring any unused medicines with you so that their use can be reviewed together.

Who can take part?

Patients with hormone receptor-positive breast cancer.

How to apply?

If you are interested in participating or would like to find out more, please speak with your physician at the Institute of Oncology Ljubljana or contact the study staff by email at [email protected].

Participation in the study is entirely voluntary and may be withdrawn at any time without any consequences. Your identity will remain anonymous, and participation in the study does not pose any risk to your health.